Developments of subunit and VLP vaccines against influenza A virus
- PMID: 22684468
- PMCID: PMC8218038
- DOI: 10.1007/s12250-012-3241-1
Developments of subunit and VLP vaccines against influenza A virus
Abstract
Influenza virus is a continuous and severe global threat to mankind. The continuously re-emerging disease gives rise to thousands of deaths and enormous economic losses each year, which emphasizes the urgency and necessity to develop high-quality influenza vaccines in a safer, more efficient and economic way. The influenza subunit and VLP vaccines, taking the advantage of recombinant DNA technologies and expression system platforms, can be produced in such an ideal way. This review summarized the recent advancements in the research and development of influenza subunit and VLP vaccines based on the recombinant expression of hemagglutinin antigen (HA), neuraminidase antigen (NA), Matrix 2 protein (M2) and nucleocapsid protein (NP). It would help to get insight into the current stage of influenza vaccines, and suggest the future design and development of novel influenza vaccines.
Similar articles
-
Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.Vaccine. 2011 Sep 22;29(41):7163-72. doi: 10.1016/j.vaccine.2011.05.077. Epub 2011 Jun 7. Vaccine. 2011. PMID: 21651946
-
Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.Hum Vaccin. 2011 Jan-Feb;7 Suppl:41-50. doi: 10.4161/hv.7.0.14561. Epub 2011 Jan 1. Hum Vaccin. 2011. PMID: 21266846
-
A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).Viral Immunol. 2007 Sep;20(3):441-52. doi: 10.1089/vim.2007.0027. Viral Immunol. 2007. PMID: 17931114
-
Influenza virus-like particle vaccines.Expert Rev Vaccines. 2009 Apr;8(4):435-45. doi: 10.1586/erv.09.8. Expert Rev Vaccines. 2009. PMID: 19348559 Review.
-
Research and development of universal influenza vaccines.Microbes Infect. 2010 Apr;12(4):280-6. doi: 10.1016/j.micinf.2010.01.001. Epub 2010 Jan 15. Microbes Infect. 2010. PMID: 20079871 Review.
Cited by
-
Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.J Cell Physiol. 2020 Dec;235(12):9098-9109. doi: 10.1002/jcp.29771. Epub 2020 Jun 18. J Cell Physiol. 2020. PMID: 32557648 Free PMC article. Review.
-
Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review.Biomedicines. 2021 May 6;9(5):520. doi: 10.3390/biomedicines9050520. Biomedicines. 2021. PMID: 34066608 Free PMC article. Review.
-
Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies.Appl Microbiol Biotechnol. 2021 Nov;105(21-22):8195-8226. doi: 10.1007/s00253-021-11615-1. Epub 2021 Oct 7. Appl Microbiol Biotechnol. 2021. PMID: 34618205 Free PMC article. Review.
-
Coronavirus Pandemic-Therapy and Vaccines.Biomedicines. 2020 May 3;8(5):109. doi: 10.3390/biomedicines8050109. Biomedicines. 2020. PMID: 32375268 Free PMC article. Review.
-
Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Cell Mol Immunol. 2016 Mar;13(2):180-90. doi: 10.1038/cmi.2015.03. Epub 2015 Feb 2. Cell Mol Immunol. 2016. PMID: 25640653 Free PMC article.
References
-
- Barefoot B. E., Sample C. J., Ramsburg E. A. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces cd8 t-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin Vaccine Immunol. 2009;16(4):488–498. doi: 10.1128/CVI.00451-08. - DOI - PMC - PubMed
-
- Biesova Z., Miller M. A., Schneerson R., et al. Preparation, characterization, and immunogenicity in mice of a recombinant influenza h5 hemagglutinin vaccine against the avian h5n1 a/vietnam/1203/2004 influenza virus. Vaccine. 2009;27(44):6234–6238. doi: 10.1016/j.vaccine.2009.07.107. - DOI - PMC - PubMed
-
- Brands R., Visser J., Medema J., et al. Influvac: A safe madin darby canine kidney (mdck) cell culture-based influenza vaccine. Dev Biol Stand. 1999;98:93–100. - PubMed
-
- Brett I. C., Johansson B. E. Immunization against influenza a virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology. 2005;339(2):273–280. doi: 10.1016/j.virol.2005.06.006. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous